Join to access to all OVN content. Join for Free
Types of Conferences MSLs Attend & How To Prepare...
Medical Science Liaisons conference strategies networking for MSLs MSL conference planning post-conference follow-up

Types of Conferences MSLs Attend & How To Prepare...


Share This Article


Summary

In this episode, George Lehman joins to discuss the strategic role of Medical Science Liaisons (MSLs) at conferences. The conversation covers the importance of conference attendance for professional development, the responsibilities MSLs hold, and effective networking strategies. George explains how MSLs decide which conferences to attend and emphasizes setting clear goals and deliverables. The episode also covers compliance in conference interactions, pre-conference planning, and best practices for post-conference follow-up. Balancing territory management with conference responsibilities is explored, concluding with final thoughts and a call to action for listeners to subscribe.

George Limen, Medical Liaison at Novo Nordisk discussed the types of conferences MSLs attend and how to prepare

George Shares….

๐Ÿ‘‰ What are the types of conferences MSLs attend and why
๐Ÿ‘‰ Who are the targets for MSLs and who do they meet
๐Ÿ‘‰ What are the basic goals for MSLs to achieve at conferences 
๐Ÿ‘‰ How do MSLs plan for events and what is the follow up routine like
๐Ÿ‘‰ Who covers the territory and how do you balance the effort when meetings happen

Click for Source
Medical Science Liaisons, conference strategies, networking for MSLs, MSL conference planning, post-conference follow-up

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%โ€‹
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%โ€‹

Explore OVN